Immunotherapy updates in pancreatic cancer: are we there yet?

doi:10.1177/1758834012462463

. 2013 Jan;5(1):81-9.

doi: 10.1177/1758834012462463.

Immunotherapy updates in pancreatic cancer: are we there yet?

Krishna Soujanya Gunturu¹, Gabriela R Rossi, Muhammad Wasif Saif

Affiliations

PMID: 23323149
PMCID: PMC3539275
DOI: 10.1177/1758834012462463

Immunotherapy updates in pancreatic cancer: are we there yet?

Krishna Soujanya Gunturu et al. Ther Adv Med Oncol. 2013 Jan.

. 2013 Jan;5(1):81-9.

doi: 10.1177/1758834012462463.

Authors

Krishna Soujanya Gunturu¹, Gabriela R Rossi, Muhammad Wasif Saif

Affiliation

¹ Division of Hematology/Onocology and Department of Medicine and Cancer Center, Tufts Medical Center, Boston, MA, USA.

PMID: 23323149
PMCID: PMC3539275
DOI: 10.1177/1758834012462463

Abstract

Pancreatic cancer is a lethal disease and remains one of the most resistant cancers to traditional therapies. Historically, chemotherapy or radiotherapy did not provide meaningful survival benefit in advanced pancreatic cancer. Gemcitabine and recently FOLFIRINOX (5-flourouracil, leucovorin, oxaliplatin and irinotecan) have provided some limited survival advantage in advanced pancreatic cancer. Targeted agents in combination with gemcitabine had not shown significant improvement in the survival. Current therapies for pancreatic cancer have their limitations; thus, we are in dire need of newer treatment options. Immunotherapy in pancreatic cancer works by recruiting and activating T cells that recognize tumor-specific antigens which is a different mechanism compared with chemotherapy and radiotherapy. Preclinical models have shown that immunotherapy and targeted therapies like vascular endothelial growth factor and epidermal growth factor inhibitors work synergistically. Hence, new immunotherapy and targeted therapies represent a viable option for pancreatic cancer. In this article, we review the vaccine therapy for pancreatic cancer.

Keywords: immunotherapy; pancreatic cancer; vaccine.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Gabriela R. Rossi has received honoraria from NewLink Genetics Corporation.

Cited by

Macrophage subsets and their role: co-relation with colony-stimulating factor-1 receptor and clinical relevance.
Yadav S, Priya A, Borade DR, Agrawal-Rajput R. Yadav S, et al. Immunol Res. 2023 Apr;71(2):130-152. doi: 10.1007/s12026-022-09330-8. Epub 2022 Oct 21. Immunol Res. 2023. PMID: 36266603 Free PMC article. Review.
Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine.
Huang X, Zhang G, Tang TY, Gao X, Liang TB. Huang X, et al. Mil Med Res. 2022 Oct 13;9(1):53. doi: 10.1186/s40779-022-00416-w. Mil Med Res. 2022. PMID: 36224645 Free PMC article. Review.
Mechanisms of the Antitumor Activity of Low Molecular Weight Heparins in Pancreatic Adenocarcinomas.
Bokas A, Papakotoulas P, Sarantis P, Papadimitropoulou A, Papavassiliou AG, Karamouzis MV. Bokas A, et al. Cancers (Basel). 2020 Feb 13;12(2):432. doi: 10.3390/cancers12020432. Cancers (Basel). 2020. PMID: 32069809 Free PMC article. Review.
Tracking Macrophage Infiltration in a Mouse Model of Pancreatic Cancer with the Positron Emission Tomography Tracer [11C]PBR28.
Lanfranca MP, Lazarus J, Shao X, Nathan H, Di Magliano MP, Zou W, Piert M, Frankel TL. Lanfranca MP, et al. J Surg Res. 2018 Dec;232:570-577. doi: 10.1016/j.jss.2018.07.015. Epub 2018 Aug 7. J Surg Res. 2018. PMID: 30463776 Free PMC article.
A Novel Monoclonal Antibody Targets Mucin1 and Attenuates Growth in Pancreatic Cancer Model.
Wu G, Maharjan S, Kim D, Kim JN, Park BK, Koh H, Moon K, Lee Y, Kwon HJ. Wu G, et al. Int J Mol Sci. 2018 Jul 9;19(7):2004. doi: 10.3390/ijms19072004. Int J Mol Sci. 2018. PMID: 29987260 Free PMC article.

See all "Cited by" articles

References

1. Abou-Alfa G., Chapman P., Feilchenfeldt J., Brennan M., Capanu M., Gansukh B., et al. (2011) Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. Am J Clin Oncol 34: 321–325 - PubMed
1. Abrams S., Khleif S., Bergmann-Leitner E., Kantor J., Chung Y., Hamilton J., et al. (1997) Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. Cell Immunol 182: 137–151 - PubMed
1. Almoguera C., Shibata D., Forrester K., Martin J., Arnheim N., Perucho M. (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53: 549–554 - PubMed
1. Bernhardt S., Gjertsen M., Trachsel S., Moller M., Eriksen J., Meo M., et al. (2006) Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer 95: 1474–1482 - PMC - PubMed
1. Bilimoria K., Bentrem D., Clifford Y., Ritchey J., Wincester D., Talamonti M. (2007) Validation of the 6th Edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer 110: 738–744 - PubMed

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database

[1] Abou-Alfa G., Chapman P., Feilchenfeldt J., Brennan M., Capanu M., Gansukh B., et al. (2011) Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. Am J Clin Oncol 34: 321–325 - PubMed

[2] Abou-Alfa G., Chapman P., Feilchenfeldt J., Brennan M., Capanu M., Gansukh B., et al. (2011) Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. Am J Clin Oncol 34: 321–325 - PubMed

[3] Abrams S., Khleif S., Bergmann-Leitner E., Kantor J., Chung Y., Hamilton J., et al. (1997) Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. Cell Immunol 182: 137–151 - PubMed

[4] Abrams S., Khleif S., Bergmann-Leitner E., Kantor J., Chung Y., Hamilton J., et al. (1997) Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. Cell Immunol 182: 137–151 - PubMed

[5] Almoguera C., Shibata D., Forrester K., Martin J., Arnheim N., Perucho M. (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53: 549–554 - PubMed

[6] Almoguera C., Shibata D., Forrester K., Martin J., Arnheim N., Perucho M. (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53: 549–554 - PubMed

[7] Bernhardt S., Gjertsen M., Trachsel S., Moller M., Eriksen J., Meo M., et al. (2006) Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer 95: 1474–1482 - PMC - PubMed

[8] Bernhardt S., Gjertsen M., Trachsel S., Moller M., Eriksen J., Meo M., et al. (2006) Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer 95: 1474–1482 - PMC - PubMed

[9] Bilimoria K., Bentrem D., Clifford Y., Ritchey J., Wincester D., Talamonti M. (2007) Validation of the 6th Edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer 110: 738–744 - PubMed

[10] Bilimoria K., Bentrem D., Clifford Y., Ritchey J., Wincester D., Talamonti M. (2007) Validation of the 6th Edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer 110: 738–744 - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Immunotherapy updates in pancreatic cancer: are we there yet?

Affiliation

Immunotherapy updates in pancreatic cancer: are we there yet?

Authors

Affiliation

Abstract

Conflict of interest statement

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources

Other Literature Sources